- Home
- PGZ vs MCRB Comparison
PGZ vs MCRB Comparison
Compare PGZ & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGZ | MCRB |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 71.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PGZ | MCRB |
|---|---|---|
| Price | $10.30 | $7.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 22.2K | ★ 107.2K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.32 | $5.31 |
| 52 Week High | $10.64 | $29.98 |
Technical Indicators
Market Signals| Indicator | PGZ | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 67.55 | 58.07 |
| Support Level | $10.29 | $6.56 |
| Resistance Level | $10.56 | $9.53 |
| Average True Range (ATR) | 0.18 | 0.62 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 91.83 | 85.64 |
Price Performance
Historical ComparisonAbout PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.